COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Mehrdad Mohseni

Dr. Mehrdad Mohseni

Scientific Review Officer


Division of Translational and Clinical Sciences DTCS
Oncology 2 - Translational Clinical IRG OTC
Study Section:
OTC Special Emphasis Panel Review ZRG1 OTC-M 08

Dr. Mehrdad Mohseni is the Scientific Review Officer for CSR‘s Oncology 2 - Translational Clinical IRG and reviews applications for research grants that address topics in a variety of areas of biomedical or clinical research.

After receiving his M.D. in 1998 and practicing as a physician in the area of general internal medicine, Dr. Mohseni had postdoctoral training in the area of apoptosis; gene polymorphism and hematology-oncology at three different clinical centers affiliated with Harvard Medical School in Boston and investigated the role of regulatory T-cells in chronic graft versus host disease.